JP2007520441A - 持続性インスリン誘導体及びその方法 - Google Patents

持続性インスリン誘導体及びその方法 Download PDF

Info

Publication number
JP2007520441A
JP2007520441A JP2006521357A JP2006521357A JP2007520441A JP 2007520441 A JP2007520441 A JP 2007520441A JP 2006521357 A JP2006521357 A JP 2006521357A JP 2006521357 A JP2006521357 A JP 2006521357A JP 2007520441 A JP2007520441 A JP 2007520441A
Authority
JP
Japan
Prior art keywords
insulin
diabetes
group
type
derivative according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006521357A
Other languages
English (en)
Japanese (ja)
Inventor
ピー． ブリドン，ドミニク
カステニュ，ジャン−ポール
ファン，シカイ
レガー，ロジャー
ロビテイル，マルティン
Original Assignee
コンジュシェム，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34118817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007520441(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by コンジュシェム，インコーポレイティド filed Critical コンジュシェム，インコーポレイティド
Publication of JP2007520441A publication Critical patent/JP2007520441A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2006521357A 2003-07-25 2004-07-26 持続性インスリン誘導体及びその方法 Pending JP2007520441A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49011003P 2003-07-25 2003-07-25
US55658504P 2004-03-25 2004-03-25
PCT/CA2004/001409 WO2005012346A1 (en) 2003-07-25 2004-07-26 Long lasting insulin derivatives and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011184958A Division JP2012062311A (ja) 2003-07-25 2011-08-26 持続性インスリン誘導体及びその方法

Publications (1)

Publication Number Publication Date
JP2007520441A true JP2007520441A (ja) 2007-07-26

Family

ID=34118817

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006521357A Pending JP2007520441A (ja) 2003-07-25 2004-07-26 持続性インスリン誘導体及びその方法
JP2011184958A Pending JP2012062311A (ja) 2003-07-25 2011-08-26 持続性インスリン誘導体及びその方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011184958A Pending JP2012062311A (ja) 2003-07-25 2011-08-26 持続性インスリン誘導体及びその方法

Country Status (15)

Country Link
US (1) US20060241019A1 (https=)
EP (2) EP2085406A1 (https=)
JP (2) JP2007520441A (https=)
AT (1) ATE433994T1 (https=)
AU (2) AU2004261319B2 (https=)
BR (1) BRPI0412252A (https=)
CA (1) CA2526957C (https=)
DE (1) DE602004021603D1 (https=)
DK (1) DK1648933T3 (https=)
EA (1) EA008433B1 (https=)
ES (1) ES2328579T3 (https=)
NO (1) NO20060888L (https=)
PL (1) PL1648933T3 (https=)
SI (1) SI1648933T1 (https=)
WO (1) WO2005012346A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518779A (ja) * 2008-04-01 2011-06-30 ノボ・ノルデイスク・エー／エス インスリンアルブミンコンジュゲート
JP2023528996A (ja) * 2020-06-09 2023-07-06 ニンポー クンペン バイオテック カンパニー，リミテッド インスリンアスパルト誘導体およびその製造方法と使用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
CA2363712C (en) * 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
ATE396202T1 (de) 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
EP1846447B1 (en) 2005-02-02 2013-08-21 Novo Nordisk A/S Insulin derivatives
MX2008014061A (es) * 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
US7982018B2 (en) 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
CN102037008B (zh) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
WO2010088286A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
EP3098235A4 (en) 2014-01-20 2017-10-18 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20160001391A (ko) * 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
AU2016258091B2 (en) 2015-05-07 2020-10-01 Codexis, Inc. Penicillin-G acylases
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
RU2764197C1 (ru) 2016-09-23 2022-01-14 Ханми Фарм. Ко., Лтд. Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
CN113855678A (zh) * 2021-09-08 2021-12-31 武汉生命奥义生物科技有限公司 一种用于辅助治疗二型糖尿病的组合物
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN115894719B (zh) * 2022-11-24 2023-10-20 武汉禾元生物科技股份有限公司 一种人血清白蛋白胰岛素偶联物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005187A1 (en) * 1993-08-13 1995-02-23 United Medical & Dental Schools Of Guy's And St Thomas' Hospitals Hepatoselective pharmaceutical actives
WO1999065941A1 (en) * 1998-06-12 1999-12-23 Kings College London Insulin analogue
JP2003527312A (ja) * 1999-05-17 2003-09-16 コンジュケム，インコーポレーテッド 長期間持続するインシュリン向性ペプチド

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509120A (en) * 1966-12-28 1970-04-28 Squibb & Sons Inc N-terminal mono- and diaminoacyl-insulin
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
EA200000453A1 (ru) * 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
AU766219B2 (en) * 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
EP1063973B1 (en) * 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
EP1121425B1 (en) * 1998-10-13 2005-06-29 The University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
PT1105409E (pt) * 1999-05-17 2006-07-31 Conjuchem Inc Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
EP1299418A1 (en) * 2000-07-10 2003-04-09 BTG INTERNATIONAL LIMITED (Company No. 2664412) Insulin derivatives and synthesis thereof
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
AU2002254940A1 (en) * 2001-03-12 2002-09-24 Novartis Pharma Gmbh Combination of nateglinide or repaglinide with at least one further antidiabetic compound
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
EP1506003A1 (en) * 2002-05-07 2005-02-16 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
US20050065066A1 (en) * 2002-12-20 2005-03-24 Kaarsholm Niels Christian Stabilised insulin compositions
GB0309154D0 (en) * 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
CA2521381C (en) * 2003-04-11 2020-05-26 Rezolute, Inc. Method for preparation of site-specific protein conjugates
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
MXPA06001283A (es) * 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
BRPI0513508B1 (pt) * 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
WO2007121256A2 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005187A1 (en) * 1993-08-13 1995-02-23 United Medical & Dental Schools Of Guy's And St Thomas' Hospitals Hepatoselective pharmaceutical actives
WO1999065941A1 (en) * 1998-06-12 1999-12-23 Kings College London Insulin analogue
JP2003527312A (ja) * 1999-05-17 2003-09-16 コンジュケム，インコーポレーテッド 長期間持続するインシュリン向性ペプチド

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518779A (ja) * 2008-04-01 2011-06-30 ノボ・ノルデイスク・エー／エス インスリンアルブミンコンジュゲート
JP2023528996A (ja) * 2020-06-09 2023-07-06 ニンポー クンペン バイオテック カンパニー，リミテッド インスリンアスパルト誘導体およびその製造方法と使用

Also Published As

Publication number Publication date
DE602004021603D1 (de) 2009-07-30
AU2011201278A1 (en) 2011-04-07
DK1648933T3 (da) 2009-09-07
HK1091843A1 (en) 2007-01-26
EP2085406A1 (en) 2009-08-05
WO2005012346A1 (en) 2005-02-10
EP1648933B1 (en) 2009-06-17
EA008433B1 (ru) 2007-06-29
EA200600305A1 (ru) 2006-06-30
NO20060888L (no) 2006-04-25
BRPI0412252A (pt) 2006-09-19
JP2012062311A (ja) 2012-03-29
ATE433994T1 (de) 2009-07-15
ES2328579T3 (es) 2009-11-16
EP1648933A4 (en) 2007-02-28
AU2004261319A1 (en) 2005-02-10
CA2526957A1 (en) 2005-02-10
CA2526957C (en) 2011-07-12
PL1648933T3 (pl) 2010-01-29
SI1648933T1 (sl) 2010-01-29
US20060241019A1 (en) 2006-10-26
EP1648933A1 (en) 2006-04-26
AU2004261319B2 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
JP2012062311A (ja) 持続性インスリン誘導体及びその方法
JP6352806B2 (ja) 新規のグルカゴン類似体
CN105307672B (zh) 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
US20120134977A1 (en) Prodrugs containing albumin binding probe
EP3873924A1 (en) Protein tyrosine-tyrosine analogs and methods of using the same
JP2002538084A (ja) グルカゴンを抑制する方法
JP7636321B2 (ja) ヒトアミリンアナログペプチド及び使用方法
US12122816B2 (en) Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
CN115867308A (zh) 延时作用的酰化胰岛素化合物
AU2018273777A1 (en) Acylated insulin compound
JP2009542217A (ja) グルカゴン様ペプチドおよびその使用
JP2024502740A (ja) 長時間作用型グルカゴン様ポリペプチド－１（ｇｌｐ－１）受容体アゴニスト及び使用方法
HK1134500A (en) Long lasting insulin derivatives and methods thereof
CN1964989B (zh) 长效胰岛素衍生物及其方法
HK1091843B (en) Long lasting insulin derivatives and methods thereof
EA052603B1 (ru) Селективные к рецептору глюкагона пептиды длительного действия и способы их применения

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100423

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110826

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110826